Tort Claims on Tylenol Rapid Release Gelcaps Expressly Preempted| FDA

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Court: Claims Challenging Marketing of Tylenol Rapid Release Gelcaps Are Expressly Preempted

Dennis Tosh

August 13, 2024 at 05:53 PM EST

A federal district court in Massachusetts has rejected a consumer’s attempt to bring a class action suit alleging that a drug manufacturer’s marketing of its over-the-counter (OTC) rapid release gelcaps was false and misleading, holding that the consumer’s claims were expressly preempted by federal law (Musikar-Rosner v. Johnson & Johnson Consumer Inc., No. 1:23-cv-11746-A... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

Court: Claims Challenging Marketing of Tylenol Rapid Release Gelcaps Are Expressly Preempted

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT